Navigation Links
A new route for tackling treatment-resistant prostate cancer
Date:7/24/2012

Scientists have identified what may be the Peyton Manning of prostate cancer. It's a protein that's essential for the disease to execute its game plan: Grow and spread throughout the body.

Like any good quarterback, this protein has command over the entire field; not only does it control cell growth in tumors that are sensitive to hormone therapy, a common treatment for men with advanced disease, but also in tumors that grow resistant to such treatment a dismal development that leaves men and their doctors with no good options to turn to.

In a study published in the Journal of Clinical Investigation, a team led by scientists from the University of Rochester Medical Center found that the protein paxillin is a major player in prostate cancer, the second most common form of cancer in men. Though in the very early stages, the discovery is an important first step towards developing a treatment for men whose cancer prevails even after the most aggressive treatment.

"The holy grail in prostate cancer is to figure out why cells stop responding to hormone therapy," said senior study author Stephen R. Hammes, M.D., Ph.D., chief of the Division of Endocrinology and Metabolism at the Medical Center. Initially, hormone therapy, which starves tumors of the hormones that fuel their growth, works well and may lead to remission. But, according to the American Cancer Society, nearly all prostate cancers treated with hormone therapy become resistant over a period of months or years and the cancer makes an unwelcome comeback.

"Somehow, tumors find a way to grow even when their main power source is choked off," noted Hammes, also the Louis S. Wolk Distinguished Professor in Medicine. "Our work is exciting because we've identified a protein pathway that controls growth even in the absence of hormones and provides a completely new treatment target for the disease."

Hammes and first author Aritro Sen, Ph.D., Research Assistant
'/>"/>

Contact: Emily Boynton
emily_boynton@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Novel drug candidates offer new route to controlling inflammation
2. Doubling down on heart failure: Researchers discover new route to disease, and drugs to match
3. New roadmap suggests proven routes to ending health disparities
4. New drug prevents spread of human prostate cancer cells
5. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
6. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
7. Study examines adverse effects among different radiation therapies for prostate cancer
8. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
9. Warren Buffett Has Early Stage Prostate Cancer
10. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
11. PSA screening to detect prostate cancer can be beneficial to younger and at-risk men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 AngelWeddingDress is now providing worldwide ... summer collections ”. When it comes to buying summer ... AngelWeddingDress with the unlimited stock of beautiful wedding gowns. ... its wonderful summer wedding gowns. , The company’s ... to keep pace with the newest fashion trends. The ...
(Date:7/11/2014)... American Farmer is proud to announce ... 15, 2014, at 8:30 am ET. , In this ... which are designed and formulated for use on a ... these products help the crop realize its maximum genetic ... grown. , The show also features UniSouth Genetics, a ...
(Date:7/11/2014)... 11, 2014 Alliance Labs announced that ... Innovations with Ed Begley Jr, airing later this year ... , In this episode, Innovations will explore DocuSol® Kids, ... sodium in polyethylene glycol base designed to give adolescents ... formulation functions as a hyperosmotic laxative by drawing water ...
(Date:7/11/2014)... 11, 2014 College athletes experiencing in-season ... of injury, but developed recurrent instability in 63% of ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Annual ... in providing the most optimal treatment plans for injured ... anterior shoulder instability event, and found that 33 (73%) ...
(Date:7/11/2014)... Anterior Cruciate Ligament (ACL) reconstructions occur more ... material used to create a new ligament may determine ... presenting their work today at the Annual Meeting of ... ). , “Our study results highlight that ... a donor) fail more frequently than using autografts (tissue ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:Intercollegiate Contact Athletes with Shoulder Instability Return to In-Season Sports, Study Shows 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... workers in the United States has risen, so has ... ,According to Vanderbilt infectious disease experts Timothy R. ... be provided to health care workers with latent TB ... particularly if they meet certain high-risk criteria. ...
... researchers has discovered a new protein called as P2 ... epithelial cells// that regulates the allergic airway inflammation. ... study that the adipocyte/macrophage fatty acid–binding protein aP2, which ... of fatty acids and has been previously linked to ...
... the open access journal Substance Abuse Treatment, Prevention and policy ... training treats the alcohol dependent patients better for a long ... by trained GPs who abstain from drinking alcohol is more ... basic training alone at the medical school. Also the ...
... duvets used by most Britons are packed with dust mites, fungus ... duvets it was found to contain up to 20,000 live house ... analysis of an 11-year unwashed duvet revealed over an ounce and ... faeces. ,In addition it was found that more than ...
... new research, the risk of heart diseases is reduced on ... the University of Bristol in the UK and colleagues conducted ... between 44 to 65, and found a direct association between ... of the thickness of blood vessel walls that is used ...
... Danish researchers, in their new studies have concluded that ... suffer from a serious heart condition when compared to ... ,Research by Kirsten Melgaard Nielsen, Ph.D., and colleagues, of ... after obtaining data on 138,000 adults between the ages ...
Cached Medicine News:Health News:Study Says - Blocking 'aP2' Protein Prevents Airway Diseases 2Health News:Dust mites use Duvets as their Haven 2Health News:Long Legs Reduces The Chances Of Heart Disease 2Health News:Significant Increase In Heart Diseases Found In Older People Living Alone 2
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year ended June 30, 2014 results on Thursday, July 31, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company ... results of a Phase 2b trial for Empatic(TM) on Wednesday, ... will be followed by a live webcast and conference call ... the call and webcast to discuss the results of this ...
... Pharmaceutical Major, Lupin Ltd. announced today the acquisition of ... mg). Lupin acquired the product from Oscient Pharmaceuticals on ... Court. Antara recorded net sales of US $ 70 ... $ 38.61 million for the product and related assets inclusive ...
Cached Medicine Technology:Lupin Expands Branded Play 2Lupin Expands Branded Play 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: